



FOR IMMEDIATE RELEASE

Rheonix, Inc. to Present Data on Rheonix CARD® Technology at AACC Annual Meeting

Ithaca, NY – July 19, 2011 – [Rheonix, Inc.](#) today announced that data demonstrating the powerful, automated molecular diagnostic capabilities of the Rheonix CARD® system will be presented in a poster session at the [American Association for Clinical Chemistry \(AACC\) Annual Meeting](#) being held in Atlanta, GA, July 24-28, 2011. Rheonix will also exhibit at the **Clinical Lab Expo, Booth #4434.**

“We now have a robust data set supporting our fully automated diagnosis of bloodstream infection from whole blood using our Rheonix CARD platform in a new application, termed SeptiCARD,” said Tony Eisenhut, President of Rheonix, Inc. “SeptiCARD is able to analyze whole blood for the presence of Septicemia agents within a three-hour period, a speed unmatched in current diagnostic procedures.”

The Rheonix SeptiCARD, still in research phase and not yet FDA cleared for *in vitro* diagnostic use, utilizes a novel dual-stage nucleic acid purification procedure designed to conduct multiplexed microbial detection for sepsis diagnosis. For the study presented, whole blood was spiked with known amounts of *Candida albicans*, *E. coli* and *enterococcus* and subsequently processed. All steps of cell lysis, dual-stage DNA purification, multiplex PCR and endpoint detection are enclosed and fully contained within the SeptiCARD, allowing for fully-automated detection and reduced risk of cross-contamination.

Rheonix Presentation at AACC:

Wednesday, July 27, 2:00 PM – 4:30 PM Eastern Time

- Presentation number D-110, “Two-step DNA Isolation Followed by PCR in a Fully Automated System to Detect Septicemia Agents in Whole Blood”

About Rheonix, Inc.

Rheonix has created a powerful microfluidic platform for the evolving molecular diagnostics industry. This system incorporates low-cost disposable Rheonix CARD® technology to analyze single or multiple clinical raw samples. The Rheonix CARD system provides multiplexed endpoint analysis and can be rapidly customized for a wide breadth of diagnostic applications. www.rheonix.com

###

Contacts:

Tony Eisenhut, President



Rheonix, Inc.:

607-257-1242, ext. 160

Media Contact:

Jacqui Miller

MacDougall Biomedical Communications

781-235-3060